Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials [Corrigendum]

This article refers to:

Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials

Toussirot E, Vauchy C, Binda D, Michel F. Drug Des Devel Ther. 2016;10:2087–2094.

On page 2089, a column heading in Table 1 was incorrectly presented. The last column heading was presented as “Golimumab 60 mg”, whereas this should have been presented as “Golimumab 100 mg” as shown below:

Table 1 Proportion of ASAS20 responders in the GO-RAISE and GO-AHEAD studies

Study	Placebo	Golimumab 50 mg	Golimumab 100 mg
GO-RAISE, primary end point at Week 14^15	21.8	59.4	60
GO-RAISE, 2 years^17	38.5	60.1	71.4
GO-AHEAD, primary end point at Week 16^16	40	71.1	NA

Abbreviations: ASAS, Assessment of SpondyloArthritis international Society; NA, not available.